Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan.

In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens.

Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

Antibacterial properties of root canal lubricants: a comparison with commonly used irrigants.

Antibiotics used most commonly to treat animals in Europe.

In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

Antibacterial synergy of curcumin with antibiotics against biofilm producing clinical bacterial isolates.

Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics.

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Fimbriation of Pseudomonas cepacia.

Activity of antibiotics against resistant Pseudomonas aeruginosa.

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

Differences in antibacterial resistance related to differences in cell envelope structure of Pseudomonas aeruginosa and Pseudomonas cepacia [proceedings].

Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source.

In vitro antibacterial activity of amikacin, a new aminoglycoside, against clinical bacterial isolates from children.

Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis.

Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria.

Pseudomonas cepacia as contaminant of propamidine disinfectants.

Green silver nanoparticles of Phyllanthus amarus: as an antibacterial agent against multi drug resistant clinical isolates of Pseudomonas aeruginosa.

Nucleotide sequence of IS402 from Pseudomonas cepacia.

Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.

Resistance plasmids in Pseudomonas cepacia 4G9.

Pseudomonas cepacia in inpatients with cystic fibrosis.

Pseudomonas cepacia infection in cystic fibrosis.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Suggest Documents

In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens.

Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

Antibacterial properties of root canal lubricants: a comparison with commonly used irrigants.

Antibiotics used most commonly to treat animals in Europe.

In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

Antibacterial synergy of curcumin with antibiotics against biofilm producing clinical bacterial isolates.

Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics.

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Fimbriation of Pseudomonas cepacia.

Activity of antibiotics against resistant Pseudomonas aeruginosa.

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

Differences in antibacterial resistance related to differences in cell envelope structure of Pseudomonas aeruginosa and Pseudomonas cepacia [proceedings].

Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source.

In vitro antibacterial activity of amikacin, a new aminoglycoside, against clinical bacterial isolates from children.

Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis.

Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria.

Pseudomonas cepacia as contaminant of propamidine disinfectants.

Green silver nanoparticles of Phyllanthus amarus: as an antibacterial agent against multi drug resistant clinical isolates of Pseudomonas aeruginosa.

Nucleotide sequence of IS402 from Pseudomonas cepacia.

Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.

Resistance plasmids in Pseudomonas cepacia 4G9.

Pseudomonas cepacia in inpatients with cystic fibrosis.

Pseudomonas cepacia infection in cystic fibrosis.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan.

Recommend Documents

Follow Us